Business Context and Reporting Period
Company: InspireMD, Inc. (NSPR)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: InspireMD is a medical device company focused on the development and commercialization of products for carotid artery disease, primarily its proprietary CGuard™ stent platform featuring MicroNet™ mesh for embolic protection. The company markets the CGuard EPS in over 30 countries (CE Mark approved) and is seeking FDA approval for the next-generation CGuard Prime system in the United States.
Key Financial Metrics
| Metric | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Revenues | $7,009 | $6,205 |
| Gross Profit | $1,506 | $1,807 |
| Gross Margin | 21.5% | 29.1% |
| Net Loss | $(32,005) | $(19,916) |
| Operating Cash Flow | $(21,868) | $(16,376) |
| Cash and Cash Equivalents | $18,916 | $9,640 |
| Marketable Securities | $15,721 | $29,383 |
| Total Liquidity (Cash + Securities) | $34,637 | $39,023 |
| Accumulated Deficit | $(253,506) | $(221,501) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 13.0% to $7.0 million, driven by growth in Europe ($772k increase), Asia ($141k), and the Middle East ($14k). This was partially offset by a $103k decline in U.S. clinical revenue due to the completion of patient enrollment in the C-GUARDIANS trial in June 2023.
- Margin Compression: Gross margin decreased from 29.1% to 21.5%. Cost of revenues increased by $1.1 million, primarily due to higher material and labor costs ($891k) associated with increased sales volume and new employee compensation.
- Expense Increases:
- R&D Expenses: Increased 70.8% to $13.6 million. Drivers included SwitchGuard NPS development ($1.4M), clinical trials for CGuardians II/III ($961k), and U.S. commercial launch preparation ($914k).
- Selling & Marketing: Increased 57.0% to $6.1 million, largely due to building the U.S. commercial sales force ($1.9M increase in compensation).
- G&A Expenses: Increased 37.8% to $15.3 million, driven by a $3.1 million increase in share-based compensation and salary expenses related to the new Miami headquarters and executive transitions.
- Capital Raises: The company received net proceeds of $16.9 million from the exercise of Series H Warrants and approximately $1.6 million from an At-The-Market (ATM) facility.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- FDA Approval Timeline: The company submitted a Premarket Approval (PMA) application in September 2024 for the CGuard Prime carotid stent system, with a view to potential FDA approval in the first half of 2025.
- Clinical Milestones: Positive one-year follow-up results from the C-GUARDIANS trial were announced in May 2024 (1.95% composite rate). The company initiated the CGUARDIANS II pivotal study for TCAR procedures in December 2024 and submitted an IDE for the CGUARDIANS III study (SwitchGuard NPS) in December 2024.
- Commercialization: Global headquarters were established in Miami, Florida, in October 2024 to support the anticipated U.S. launch. Manufacturing of CGuard Prime is being transferred to a contract manufacturer (Aptyx) in North Carolina to scale production.
Risks and Contingencies
- Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern. The company does not have sufficient resources to fund operations for at least the next 12 months without additional financing.
- Liquidity Needs: The company will need to raise additional capital to fund U.S. commercialization, manufacturing expansion, and ongoing R&D. Failure to secure financing could force a curtailment of operations.
- Geopolitical Risk: Manufacturing facilities and key personnel are located in Israel. Ongoing conflict in the region poses risks to operations, supply chains, and personnel availability, though operations have not been materially disrupted to date.
- Regulatory Risk: There is no assurance that the PMA application will be approved or that the company will meet the milestones required to exercise remaining warrants (Series I, J, K).
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of current cash ($18.9M) and marketable securities ($15.7M) against the burn rate of ~$22M annually to confirm the timeline for the next capital raise.
- Warrant Milestones: Monitor the status of the PMA approval and commercial sales milestones, as these trigger the expiration of Series I, J, and K warrants (totaling ~38.7M shares).
- Manufacturing Transition: Confirm the successful transfer of CGuard Prime production to the Aptyx facility in North Carolina and the validation of the new PET resin supplier.
- Israel Operations: Assess the impact of the ongoing conflict in Israel on the Tel Aviv manufacturing facility and employee availability.
- Reimbursement: Track the implementation of the CMS National Coverage Determination (NCD) for CAS and TCAR to ensure market access in the U.S. upon approval.